Comparison of intracoronary versus intravenous administration of tirofiban in primary percutaneous coronary intervention;Primer perkütan koroner girişim uygulanan hastalarda tirofibanin intrakoroner ve intravenöz bolus dozlarinin karşilaştirilmasi

Anadolu Kardiyoloji Dergisi

Volumn 10, Issue 4, 2010, Pages 340-345

  Erdim, Refik ^a   Erciyes, Demet ^a   Görmez, Selçuk ^a   Karabay, Kanber Öcal ^a   Çatakoǧlu, Alp Burak ^a   Aytekin, Vedat ^a   Demiroǧlu, Cemşid ^a   Gülbaran, Murat ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Coronary stenting; Glycoprotein IIb IIIa inhibitors; Myocardial infarction

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; PHOSPHOTRANSFERASE; TIROFIBAN;

ADULT; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; ENZYME RELEASE; FATALITY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INTRACORONARY DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REOPERATION; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CREATINE KINASE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; TYROSINE;

EID: 77955831993     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2010.093     Document Type: Article

References (27)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
2. Zijlstra F, Hoorntje JC, De Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341: 1413-9.
3. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879-85.
4. Wöhrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107:1840-3.
5. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GGL, Giannico F, Crea F. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007; 23: 57-63.
6. Peerlinck K, De Lepeleire I, Goldberg M, Farrel D, Barrett J, Hand E, et al. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993; 88: 1512-7.
7. Lee DP, Herity NA, Hiat BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: Results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation 2003; 107: 1497-501.
8. Wu TG, Zhao Q, Huang WG, Wei JR, Chen SW, Zhao J, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J 2008; 72: 1605-9.
9. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Eng J Med 1985; 312: 932-6.
10. EPISTENT investigators. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
11. Theroux P, Catella-Lawson F, Charbonnier B, Diodati J, Kouz S, Nasmith J, et al. for the PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
12. Topol E, Califf R, Simoons M, Diaz R, Paolasso E, Klein W, et al. for the PURSUIT Study Group. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebocontrolled, clinical trial. N Engl J Med 1998; 339: 436-43.
13. Brener S, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. For the RAPPORT Investigators. Randomized, placebo-controlled trial of glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734-41.
14. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Grifin JJ, et al. For the CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-66.
15. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY Randomized Trial. JAMA 2008; 299: 1788-99.
16. Marzocchi A, Manari A, Piovaccari G, Marrozzini C, Marra S, Magnavacchi P, et al. For the FATA investigators. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 2008; 29: 2972-80.
17. Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, et al. For the FATA investigators. Left ventricular function after ST elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the facilitated angioplasty with tirofiban or abciximab [FATA] trial). Am J Cardiol 2009; 103: 785-90.
18. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST segment elevation myocardial infarction treated with primary angioplasty. J Am Coll Cardiol 2009; 53: 1668-73.
19. Romagnoli E, Burzotta F, Trani C, Mazzari MA, Biondi-Zoccai GG, De Vita M, et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 2005; 105: 250-5.
20. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004; 62: 186-92.
21. Wöhrle J, Nusser T, Mayer C, Kochs M, Hombach V. Intracoronary application of abciximab in patients with ST-elevation myocardial infarction. Eurointervention 2007; 3: 465-9.
22. Yang TY, Chang ST, Chung CM, Cheng NJ. Restoration of normal coronary flow with tirofiban by intracoronary administration fo noreflow phenomenon after stent deployment. Int Heart J 2005; 46: 139-45.
23. Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kübler W. Troponin T concentration concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 2002; 87: 520-4.
24. Halkin A, Stone GW, Grines CL, Cox DA, Rutherford BD, Esente P, et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2006; 47: 951-61.
25. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91:334-6.
26. Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high risk percutaneous coronary intervention. Am J Cardiol 2006; 97: 489-93.
27. Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST segment elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 1187-93.